{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:21:29Z","timestamp":1792081289811,"version":"4.4.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001453","name":"American Brain Tumor Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Musella Foundation for Brain Tumor Research & Information, Inc., National Brain Tumor Society"},{"DOI":"10.13039\/100001794","name":"Pediatric Brain Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006064","name":"The Sontag Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019451","name":"Uncle Kory Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019451","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zelda Dorin Tetenbaum Memorial Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Years of life lost (YLL) is a disease burden measure quantifying the number of years lost due to premature mortality for a given disease. The present study sought to assess YLL for primary brain and other central nervous system (CNS) tumor histopathologies in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mortality, incidence, and life expectancy data for mortalities occurring in 2018 were obtained from the National Vital Statistics System and the National Program of Cancer Registries. Tumor-specific YLL were estimated by subtracting age of death from projected life expectancy; mean YLL (mYLL) was determined to assess the impact of CNS tumor diagnosis on the individual patient level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For mortalities occurring in 2018, the total YLL due to malignant CNS tumors was 364\u00a0223 years (mYLL\u2005=\u200521.2 years), compared to 15\u00a0472 years (mYLL\u2005=\u200514.2 years) for nonmalignant tumors. Glioblastoma had the highest total YLL among malignant CNS tumors (58.8% of all primary CNS tumor YLL; mYLL\u2005=\u200519.8 years), and nonmalignant meningioma among nonmalignant CNS tumors (2.9% of all primary CNS tumor YLL; mYLL\u2005=\u200514.4 years). Malignant pediatric tumors had the greatest mYLL, with medulloblastoma having a mYLL of 61.2 years and other embryonal tumors having an mYLL of 50.7.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Malignant CNS tumors, glioblastoma in particular, contributed the most to total YLL, whereas pediatric CNS malignancies had the greatest mYLL. Used with other epidemiological data, the authors contend that this quantification may help rationalize the allocation of clinical and research resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf142","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:38:33Z","timestamp":1749541113000},"page":"2738-2746","source":"Crossref","is-referenced-by-count":9,"title":["Years of life lost due to central nervous system tumor subtypes in the United States"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-0517","authenticated-orcid":false,"given":"Jakob V E","family":"Gerstl","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Brigham and Women\u2019s Hospital, Mass General Brigham, Harvard Medical School , Boston, Massachussetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-3867","authenticated-orcid":false,"given":"Joshua D","family":"Bernstock","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brigham and Women\u2019s Hospital, Mass General Brigham, Harvard Medical School , Boston, Massachussetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Kruchko","sequence":"additional","affiliation":[{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennard","family":"Spanehl","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brigham and Women\u2019s Hospital, Mass General Brigham, Harvard Medical School , Boston, Massachussetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramesh V","family":"Karandikar","sequence":"additional","affiliation":[{"name":"Chan School of Medicine, University of Massachusetts , Worcester, Massachussetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S","family":"Barnholtz-Sloan","sequence":"additional","affiliation":[{"name":"Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute , Bethesda, Maryland ,","place":["USA"]},{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brigham and Women\u2019s Hospital, Mass General Brigham, Harvard Medical School , Boston, Massachussetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B","family":"Claus","sequence":"additional","affiliation":[{"name":"School of Public Health, Yale University , New Haven, Connecticut ,","place":["USA"]},{"name":"Department of Neurosurgery, Brigham and Women\u2019s Hospital, Mass General Brigham, Harvard Medical School , Boston, Massachussetts,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3469-7558","authenticated-orcid":false,"given":"Quinn T","family":"Ostrom","sequence":"additional","affiliation":[{"name":"The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Department of Neurosurgery, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Central Brain Tumor Registry of the United States , Hinsdale, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"issue":"Suppl_6","key":"2026012603470283300_CIT0001","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"issue":"4","key":"2026012603470283300_CIT0002","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1474-4422(18)30468-X","article-title":"Global, regional, and national burden of brain and other CNS cancer, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Patel","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"2026012603470283300_CIT0003","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/neuonc\/nov249","article-title":"Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010","volume":"18","author":"Rouse","year":"2016","journal-title":"Neuro Oncol"},{"issue":"6","key":"2026012603470283300_CIT0004","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3171\/2022.9.JNS221499","article-title":"A national stratification of the global macroeconomic burden of central nervous system cancer","volume":"138","author":"Gerstl","year":"2022","journal-title":"J Neurosurg."},{"key":"2026012603470283300_CIT0005","author":"Institute for Health Metrics and Evaluation","journal-title":"Global Burden of Disease Compare Tool"},{"issue":"9908","key":"2026012603470283300_CIT0006","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/S0140-6736(13)62105-4","article-title":"Global health 2035: a world converging within a generation","volume":"382","author":"Jamison","year":"2013","journal-title":"Lancet."},{"issue":"3","key":"2026012603470283300_CIT0007","first-page":"495","article-title":"The Global Burden of Disease in 1990: summary results, sensitivity analysis and future directions","volume":"72","author":"Murray","year":"1994","journal-title":"Bull World Health Organ."},{"issue":"10440","key":"2026012603470283300_CIT0008","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Global Burdern Disease Study 2021 Diseases and Injuries Collaborators","year":"2024","journal-title":"Lancet."},{"issue":"12 Suppl 2","key":"2026012603470283300_CIT0009","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026012603470283300_CIT0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/neuonc\/noy006","article-title":"The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone","volume":"20","author":"Kruchko","year":"2018","journal-title":"Neuro Oncol."},{"key":"2026012603470283300_CIT0011","year":"1999"},{"issue":"12","key":"2026012603470283300_CIT0012","first-page":"1117","article-title":"The surveillance, epidemiology, and end results program: a national resource","volume":"8","author":"Hankey","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"2026012603470283300_CIT0013","author":"U.S. Cancer Statistics Working Group","year":"2021"},{"key":"2026012603470283300_CIT0014","author":"Surveillance Epidemiology and End Results (SEER) Program","year":"2023"},{"key":"2026012603470283300_CIT0015","author":"National Cancer Institute","journal-title":"Cancer Trends Progress Report: Years of Life Lost"},{"issue":"Suppl 5","key":"2026012603470283300_CIT0016","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"9","key":"2026012603470283300_CIT0017","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/STROKEAHA.123.043131","article-title":"Global, regional, and national economic consequences of stroke","volume":"54","author":"Gerstl","year":"2023","journal-title":"Stroke."},{"issue":"3","key":"2026012603470283300_CIT0018","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1162\/rest.90.3.573","article-title":"Adjusting the value of a statistical life for age and cohort effects","volume":"90","author":"Aldy","year":"2008","journal-title":"Rev Econ Stat"},{"issue":"1","key":"2026012603470283300_CIT0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/cer-2016-0021","article-title":"Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers","volume":"6","author":"Wang","year":"2017","journal-title":"J Comp Eff Res."},{"issue":"1","key":"2026012603470283300_CIT0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13023-024-03097-x","article-title":"Analysis of the first ten years of FDA\u2019s rare pediatric disease priority review voucher program: designations, diseases, and drug development","volume":"19","author":"Mease","year":"2024","journal-title":"Orphanet J Rare Dis."},{"issue":"9","key":"2026012603470283300_CIT0021","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","article-title":"Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014","volume":"4","author":"Ostrom","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf142\/63492688\/noaf142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/10\/2738\/63492688\/noaf142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/10\/2738\/63492688\/noaf142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:47:16Z","timestamp":1769417236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/10\/2738\/8162922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,15]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf142","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,15]]}}}